NEW YORK, October 23, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting UnitedHealth Group Inc. (NYSE: UNH), Humana Inc. (NYSE: HUM), Align Technology, Inc. (NASDAQ: ALGN), Sanofi SA (ADR) (NYSE: SNY) and Anacor Pharmaceuticals Inc. (NASDAQ: ANAC). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
UnitedHealth Group Inc. Research Report
On October 17, 2013, UnitedHealth Group, Inc. (UnitedHealth Group) reported its Q3 2013 results. The Company stated that its total revenues increased 12.2% YoY to $30.6 billion during the quarter, and its net earnings attributable to common shareholders increased marginally by 0.8% YoY to $1.6 billion. Diluted EPS per share came in at $1.53 in Q3 2013, compared to $1.50 per diluted share in Q3 2012. Commenting on the results, Stephen J. Hemsley, President and CEO of UnitedHealth Group, said, "We are pleased to have grown and advanced by serving individual health care needs and the ever-changing demands of the health care system at large." The Company also stated that it has narrowed its outlook for full-year 2013 net earnings to $5.40 - $5.50 per share. The Full Research Report on UnitedHealth Group Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/73e5_UNH]
Humana Inc. Research Report
On October 17, 2013, Humana Inc. (Humana) announced that it has achieved strong Medicare Stars Quality Ratings for its Medicare Advantage (MA) plans. The Company stated that these Humana MA plans, available to Medicare beneficiaries during the Medicare Annual Election Period (AEP), which began on October 15, 2013 and runs through December 7, 2013, will take effect on January 1, 2014. Humana added that many of its MA plans that will be available in 2014 have higher Medicare Stars quality ratings than in years past. Humana informed that it has 18 MA plans that achieved a rating of 4.0 stars or greater. Further, the Company said that 55% of 2013 Humana MA Membership is participating in 2014 plans rated 4.0 stars or greater. Humana is also offering nine MA plans that achieved a 4.5 star rating. Lastly, Humana stated that its MA HMO plans in Florida, Mississippi, North Carolina, and Oregon were again rated 4.5 stars. The Full Research Report on Humana Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/496b_HUM]
Align Technology, Inc. Research Report
On October 17, 2013, Align Technology, Inc. (Align Technology) announced its Q3 2013 financial results. The Company reported that its net revenues increased 20.5% YoY to $164.5 million during the quarter. Align Technology stated that its net profit stood at $34.5 million or $0.42 per diluted share in Q3 2013, compared to net loss of $0.3 million or $0.00 per diluted share in Q3 2012. Commenting on the results, Thomas M. Prescott, Align Technology's President and CEO, said, "The third quarter includes a seasonally slower period in Europe and in North America for our GP dentists, along with the peak of the summer season for teenage orthodontic case starts. We're pleased that patient traffic appears to have remained solid for our North American Orthodontist customers this summer, which resulted in strong sequential and year over year growth for Invisalign volume, especially in the important teenage segment." The Full Research Report on Align Technology, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/69b3_ALGN]
Sanofi SA (ADR) Research Report
On October 16, 2013, Sanofi SA (ADR) (Sanofi) and Regeneron Pharmaceuticals (Regeneron) announced that the Phase 3 ODYSSEY MONO trial with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) met its primary efficacy endpoint. Sanofi stated that the mean low-density lipoprotein cholesterol (LDL-C, or "bad" cholesterol) reduction from baseline to week 24, the primary efficacy endpoint of the study, was significantly greater in patients randomized to alirocumab, in comparison to patients randomized to ezetimibe (47.2% vs. 15.6%, p<0.0001). Sanofi added that in the trial, which employed a dose increase (up-titration) for patients who did not achieve LDL-C level of 70 milligrams/deciliter (mg/dL), the majority of patients remained on the initial low dose of alirocumab of 75 mg. The Full Research Report on Sanofi SA (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/29ea_SNY]
Anacor Pharmaceuticals Inc. Research Report
On October 17, 2013, Anacor Pharmaceuticals Inc. (Anacor) announced that the arbitrator appointed to resolve its dispute with Valeant Pharmaceuticals, Inc. (Valeant) successor in interest to Dow Pharmaceutical Sciences, Inc. (DPS), has issued an Interim Final Award in favor of Anacor, and that it has been awarded $100 million in damages as well as all costs of the arbitration and reasonable attorney's fees. The Company stated that the Final Award will be submitted to the court of appropriate jurisdiction for confirmation and enforcement. Anacor said that the timeframe for this legal process is subject to the court's time schedule, but the Company expects confirmation of the award before the end of 2013, at which point the judgment will become enforceable. The Full Research Report on Anacor Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/05d8_ANAC]
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner